Atlas Trials

Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

Clinical trial NCT03167151 · TERMINATED

Trial details

NCT number
NCT03167151
Sponsor
University of Oxford
Status
TERMINATED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Non-muscle Invasive Bladder Cancer (NMIBC)
Start date
2018-03-02
Primary completion
2019-03-26
Enrollment
6

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.